Literature DB >> 23977540

Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Nico van Zandwijk1, Glen Reid, Anthony Linton, Steven Kao.   

Abstract

Entities:  

Year:  2012        PMID： 23977540      PMCID： PMC3741798          DOI： 10.3978/j.issn.2225-319X.2012.10.01

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN： 2225-319X


× No keyword cloud information.
  56 in total

1.  Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.

Authors:  Ottavio Rena; Caterina Casadio
Journal:  Lung Cancer       Date:  2012-01-11       Impact factor: 5.705

2.  The MARS feasibility trial: conclusions not supported by data.

Authors:  Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

Review 3.  The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma.

Authors:  Anthony Linton; Janette Vardy; Stephen Clarke; Nico van Zandwijk
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-27       Impact factor: 6.312

4.  Malignant pleural mesothelioma: a population-based study of survival.

Authors:  Michael T Milano; Hong Zhang
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

5.  Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?

Authors:  Apostolos Nakas; Edward Black; James Entwisle; Salli Muller; David A Waller
Journal:  Eur J Cardiothorac Surg       Date:  2010-02-06       Impact factor: 4.191

6.  Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.

Authors:  Federico Rea; Giuseppe Marulli; Luigi Bortolotti; Cristiano Breda; Adolfo Gino Favaretto; Lucio Loreggian; Francesco Sartori
Journal:  Lung Cancer       Date:  2007-04-02       Impact factor: 5.705

7.  Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.

Authors:  Steven Chuan-Hao Kao; Nicola Armstrong; Bridget Condon; Kim Griggs; Brian McCaughan; Sarah Maltby; Alan Wilson; Douglas W Henderson; Sonja Klebe
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

8.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

9.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.

Authors:  David J Sugarbaker; Michael T Jaklitsch; Raphael Bueno; William Richards; Jeanne Lukanich; Steven J Mentzer; Yolonda Colson; Phillip Linden; Michael Chang; Leah Capalbo; Elizabeth Oldread; Siyamek Neragi-Miandoab; Scott J Swanson; Lambros S Zellos
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

10.  The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.

Authors:  E F Patz; V W Rusch; R Heelan
Journal:  AJR Am J Roentgenol       Date:  1996-02       Impact factor: 3.959
View more
  2 in total

1.  Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.

Authors:  Ilaria Bononi; Manola Comar; Andrea Puozzo; Mariarita Stendardo; Piera Boschetto; Sara Orecchia; Roberta Libener; Roberto Guaschino; Silvia Pietrobon; Manuela Ferracin; Massimo Negrini; Fernanda Martini; Massimo Bovenzi; Mauro Tognon
Journal:  Oncotarget       Date:  2016-12-13

2.  Does size matter? -a population-based analysis of malignant pleural mesothelioma.

Authors:  Jiaxi He; Songhui Xu; Hui Pan; Shuben Li; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.